Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 30

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 30
---
20+ years of experience are essential to Dynavax as we continue executing on our long - term strategy Deep Track’s Campaign Would Remove Essential Vaccine Expertise Crucial to our Growth 40 | Brent MacGregor Independent Director since July 2020 x Highly experienced vaccine executive: Head of Novartis Vaccines North America, and then led global operations of influenza vaccines portfolio at the company, until the $275M acquisition of the division by CSL/Seqirus x Extensive vaccine commercialization and development background: as SVP commercial operations at Seqirus, Mr. MacGregor led a global team of 280 people in sales, marketing, commercial development, public policy and business development for a portfolio of seasonal influenza vaccines x International vaccine expertise: Mr. MacGregor spent 17 years at Sanofi Pasteur, with his final role as President, Sanofi Pasteur KK, Tokyo, Japan. In his time there he worked in markets including United States, Canada, France, Australia/New Zealand, and Japan Selected Recent Public Company Experience ▪ CEO | Medical Developments International (ASX: MVP) vs © Copyright DYNAVAX 2025 Donald Santel Former President and CEO of Hyperion Therapeutics, a pharmaceutical company focused on rare disease that was acquired in 2015 No relevant vaccine experience: Prior executive roles focused on pharmaceutical treatments of rare disease as well as medical devices No additive skillsets to our board: No additional or differentiated perspective or skills relative to our current Board No recent public company executive experience: Last public C - suite experience was in 2015 Lackluster track record of value creation: Majority of public Board directorship tenures have resulted in negative relative TSRs

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Michael Mullette Former Interim CEO of Lykos Therapeutics, a privately - held pharmaceutical company developing MDMA for potential medicinal use Limited healthcare C - Suite experience: Served as the COO and Interim CEO of Lykos. The company laid off 75% of its workforce in August 2024 after the U.S. Food and Drug Administration declined approval for its MDMA - based therapy for PTSD No additive skillsets to our board: No additional or differentiated perspective or skills relative to our current Board Public Biotech Executive Experience None Public Company Board Experience